{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:39:00Z","timestamp":1791517140394,"version":"4.3.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The distinction between chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) with isolated Hodgkin\/Reed\u2013Sternberg cells (CLL-HRS; background milieu with a paucity of inflammatory cells) and overt transformation to classic Hodgkin lymphoma (CLL-HL; mixed inflammatory background) is incompletely understood. This retrospective study examined the clinicopathologic features of CLL-HRS (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200915) and CLL-HL (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200931) patients seen over the past three decades from a single institution. The phenotypic features of Reed\u2013Sternberg cells in both groups were similar, including expression of CD30, CD15, and PAX5, as well as EBV status. However, a spectrum of background CLL\/SLL infiltration amongst the HRS cells was noted on pathologic review, and four patients had both diagnoses, either concurrently or in succession. The median overall survival (OS) of patients with CLL-HRS was 17.5\u2009months compared to 33.5\u2009months for patients with CLL-HL (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.24). Among patients with CLL-HRS, those who received Hodgkin-directed therapy had a significantly longer median OS (57\u2009months) compared to those who received CLL-directed therapy (8.4\u2009months,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.02). Our clinical and pathologic findings suggest a biologic continuum between CLL-HRS and CLL-HL and indicate that CLL-HRS patients may benefit from Hodgkin-directed therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41408-022-00616-6","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T03:03:48Z","timestamp":1643339028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Chronic lymphocytic leukemia (CLL) with Reed\u2013Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7132-0226","authenticated-orcid":false,"given":"Rebecca L.","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2427-5837","authenticated-orcid":false,"given":"Paul J.","family":"Kurtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9811-4601","authenticated-orcid":false,"given":"Wei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Call","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7313-1875","authenticated-orcid":false,"given":"Kari G.","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2767-3830","authenticated-orcid":false,"given":"Saad S.","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose F.","family":"Leis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Schwager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5173-4712","authenticated-orcid":false,"given":"Susan L.","family":"Slager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5951-5055","authenticated-orcid":false,"given":"Neil. E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1244-6758","authenticated-orcid":false,"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Inwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-4293","authenticated-orcid":false,"given":"Min","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3221-7314","authenticated-orcid":false,"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"616_CR1","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/ajh.23939","volume":"90","author":"SA Parikh","year":"2015","unstructured":"Parikh SA, Habermann TM, Chaffee KG, Call TG, Ding W, Leis JF, et al. Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma. Am J Hematol. 2015;90:334\u20138.","journal-title":"Am J Hematol"},{"key":"616_CR2","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1002\/ijc.21716","volume":"118","author":"A Br\u00e4uninger","year":"2006","unstructured":"Br\u00e4uninger A, Schmitz R, Bechtel D, Renn\u00e9 C, Hansmann ML, K\u00fcppers R. Molecular biology of Hodgkin\u2019s and Reed\/Sternberg cells in Hodgkin\u2019s lymphoma. Int J Cancer. 2006;118:1853\u201361.","journal-title":"Int J Cancer"},{"key":"616_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/blood.V95.3.1023.003k07_1023_1031","volume":"95","author":"H Kanzler","year":"2000","unstructured":"Kanzler H, K\u00fcppers R, Helmes S, Wacker HH, Chott A, Hansmann ML, et al. Hodgkin and Reed\u2013Sternberg-like cells in B-cell chronic lymphocytic leukemia represent the outgrowth of single germinal-center B-cell-derived clones: potential precursors of Hodgkin and Reed\u2013Sternberg cells in Hodgkin\u2019s disease. Blood. 2000;95:1023\u201331.","journal-title":"Blood."},{"key":"616_CR4","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","volume":"31","author":"Z Mao","year":"2007","unstructured":"Mao Z, Quintanilla-Martinez L, Raffeld M, Richter M, Krugmann J, Burek C, et al. IgVH mutational status and clonality analysis of Richter\u2019s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surgical Pathol. 2007;31:1605\u201314.","journal-title":"Am J Surgical Pathol"},{"key":"616_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/00000478-199209000-00004","volume":"16","author":"H Momose","year":"1992","unstructured":"Momose H, Jaffe ES, Shin SS, Chen YY, Weiss LM. Chronic lymphocytic leukemia\/small lymphocytic lymphoma with Reed- Sternberg-like cells and possible transformation to Hodgkin\u2019s disease: mediation by Epstein\u2013-Barr virus. Am J Surgical Pathol. 1992;16:859\u201367.","journal-title":"Am J Surgical Pathol"},{"key":"616_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s004280000214","volume":"437","author":"E Pescarmona","year":"2000","unstructured":"Pescarmona E, Pignoloni P, Mauro FR, Cerretti R, Anselmo AP, Mandelli F, et al. Hodgkin\/Reed\u2013Sternberg cells and Hodgkin\u2019s disease in patients with B-cell chronic lymphocytic leukaemia: an immunohistological, molecular and clinical study of four cases suggesting a heterogeneous pathogenetic background. Virchows Arch. 2000;437:129\u201332.","journal-title":"Virchows Arch"},{"key":"616_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.humpath.2016.04.019","volume":"55","author":"W Xiao","year":"2016","unstructured":"Xiao W, Chen WW, Sorbara L, Davies-Hill T, Pittaluga S, Raffeld M, et al. Hodgkin lymphoma variant of Richter transformation: morphology, Epstein\u2013Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion. Hum Pathol. 2016;55:108\u201316.","journal-title":"Hum Pathol"},{"key":"616_CR8","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, editors. WHO classification of tumors of haematopoetic and lymphoid tissues. 4th ed. IARC: Lyon; 2017."},{"key":"616_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1365-2141.2011.08907.x","volume":"156","author":"B Bockorny","year":"2012","unstructured":"Bockorny B, Codreanu I, Dasanu CA. Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. Br J Haematol. 2012;156:50\u201366.","journal-title":"Br J Haematol"},{"key":"616_CR10","doi-asserted-by":"crossref","unstructured":"Stephens DM, Boucher K, Kander E, Parikh SA, Parry EM, Shadman M, et al. Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica. 2020;106:2845\u201352.","DOI":"10.3324\/haematol.2020.256388"},{"key":"616_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","volume":"35","author":"O Al-Sawaf","year":"2021","unstructured":"Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, VT J, et al. Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 2021;35:169\u201376.","journal-title":"Leukemia."},{"key":"616_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/00000478-200405000-00018","volume":"28","author":"L De Leval","year":"2004","unstructured":"De Leval L, Vivario M, De Prijck B, Zhou Y, Boniver J, Harris NL, et al. Distinct clonal origin in two cases of Hodgkin\u2019s lymphoma variant of Richter\u2019s syndrome associated with EBV infection. Am J Surgical Pathol. 2004;28:679\u201386.","journal-title":"Am J Surgical Pathol"},{"key":"616_CR13","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1182\/blood.V91.5.1757","volume":"91","author":"T Ohno","year":"1998","unstructured":"Ohno T, Smir BN, Weisenburger DD, Gascoyne RD, Hinrichs SD, Chan WC. Origin of the Hodgkin\/Reed\u2013Sternberg cells in chronic lymphocytic leukemia with \u201cHodgkin\u2019s transformation\u201d. Blood. 1998;91:1757\u201361.","journal-title":"Blood."},{"key":"616_CR14","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin\u2019s disease. International prognostic factors project on advanced Hodgkin\u2019s disease. N. Engl J Med. 1998;339:1506\u201314.","journal-title":"N. Engl J Med"},{"key":"616_CR15","first-page":"91","volume":"7","author":"D Rubin","year":"1994","unstructured":"Rubin D, Hudnall SD, Aisenberg A, Jacobson JO, Harris NL. Richter\u2019s transformation of chronic lymphocytic leukemia with Hodgkin\u2019s-like cells is associated with Epstein\u2013Barr virus infection. Mod Pathol. 1994;7:91\u20138.","journal-title":"Mod Pathol."},{"key":"616_CR16","first-page":"785","volume":"34","author":"T Tadmor","year":"2014","unstructured":"Tadmor T, Shvidel L, Goldschmidt N, Ruchlemer R, Fineman R, Bairey O, et al. Hodgkin\u2019s variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group. Anticancer Res. 2014;34:785\u201390.","journal-title":"Anticancer Res"},{"key":"616_CR17","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/bjh.12458","volume":"162","author":"SA Parikh","year":"2013","unstructured":"Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, et al. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013;162:774\u201382.","journal-title":"Br J Haematol"},{"key":"616_CR18","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1002\/cncr.25292","volume":"116","author":"TD Shanafelt","year":"2010","unstructured":"Shanafelt TD, Rabe KG, Kay NE, Zent CS, Jelinek DF, Reinalda MS, et al. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer. 2010;116:4777\u201387.","journal-title":"Cancer."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00616-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T15:02:41Z","timestamp":1669215761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00616-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["616"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00616-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"14 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SAP: Research funding has been provided to the institution from Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which Sameer A. Parikh is a principal investigator (these funds are unrelated to the work presented in this manuscript). Sameer A. Parikh has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, GlaxoSmithKline, Innate Pharma, Adaptive Biotechnologies, and AbbVie (he was not personally compensated for his participation). NEK: Research funding from Acerta Pharm, Pharmacyclics, MEI Pharma, and Tolero. He is on a data safety monitoring committee for Agios Pharm, Celgene, Sunesis, Cytomx Therapeutics, MorphoSys, Rigel Pharmaceuticals, and Juno Therapeutics. He is on an advisory Board for AstraZeneca, Cytomx Therapeutics, Pharmacyclics Dava Oncology, Acerta Pharma BV, and Juno Therapeutics. WD: Research funding from Merck and DTRM. Advisory board: Merck and Octapharma (no personal compensation). YW: Research funding (to the institution) from Incyte, InnoCare, Novartis, and Genentech. SSK: patents and royalties in the field of CART cell therapy from Novartis, Humanigen, Mettaforge, and Morphosys. Research Funding: Novartis, Kite\/Gilead, Juno\/BMS, Humanigen, Morphosys, Lentigen, Tolero, Sunesis, and LeahLabs. Advisory Board: Kite, Juno, and Humanigen. Data Safety Monitoring Board: Humanigen. TMH: is on data monitoring committees for Seagen and Tess Therapeutics. TMH is a member of the Scientific advisory boards for Lilly, Morphosys, and Incyte. TMH receives no personal income from these activities. RLK: Research funding (to the institution) from Bristol-Myers Squibb\/Celgene. The remaining authors have no conflicts of interest to declare relative to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}